- Tytuł:
- Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study
- Autorzy:
- Źródło:
- In ESMO Open January 2024 9(1)
Czasopismo naukowe